NCT07147647 Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma
| NCT ID | NCT07147647 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Select Eye Care |
| Condition | Primary Open Angle Glaucoma (POAG) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-07-16 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-07-16 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to to evaluate how well Direct Selective Laser Trabeculoplasty (DSLT) lowers eye pressure in eyes of adult, non-Caucasian participants with primary open angle glaucoma. The main question it aims to answer is: What is the washed out eye pressure (eye pressure when not on any glaucoma medications) of participants 6 months after the Direct Selective Laser Trabeculoplasty (DSLT) procedure compared to the washed out eye pressure of participants prior to the DSLT procedure. Participants will: Undergo the DSLT procedure in one or both eyes and visit the clinic 1 month, 3 months, and 6 months after the procedure to have their vision and eye pressure measured.
Eligibility Criteria
Inclusion Criteria: * Adult patients of Black African descent scheduled to undergo DSLT treatment in one or both eyes. * Diagnosis of mild to moderate primary open angle glaucoma (POAG). * Mild to moderate POAG will be defined as Stage 2 or better of the Hodapp-Anderson-Parrish glaucoma staging system. * Treatment naive or washed out IOP at time 0 ranging from ≥ 21 through 32 mm Hg. Exclusion Criteria: * Screened patients who were on IOP-lowering medications who did not successfully complete medication washout at the time of the procedure (time 0). * Previous glaucoma surgeries/interventions: * Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt). * Secondary glaucoma: * Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases. * Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator. * Subjects who are pregnant, breast-feeding, or intend to become pregnant during the study period as determined by verbal inquiry.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07147647 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Primary Open Angle Glaucoma (POAG). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07147647 currently recruiting?
Yes, NCT07147647 is actively recruiting participants. Contact the research team at scott.laborwit@vipeyes.com for enrollment information.
Where is the NCT07147647 trial being conducted?
This trial is being conducted at Elkridge, United States.
Who is sponsoring the NCT07147647 clinical trial?
NCT07147647 is sponsored by Select Eye Care. The trial plans to enroll 60 participants.